Lv23
169 积分 2025-02-06 加入
Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non−Small Cell Lung Cancer
23小时前
已完结
Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China
7天前
已完结
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China
7天前
已完结
Modulating pMMR colorectal tumors toward a dMMR-like phenotype by Xian-Lian-Jie-Du decoction enhances anti-PD-1 efficacy
12天前
已完结
Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
13天前
已完结
STING reprogramming by estrogen promotes neutrophil extracellular trap formation and sex-biased resistance to ADC therapy
26天前
已完结
First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2–Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT)
1个月前
已完结
Clinician’s Guide to the 2024 VA/DoD Clinical Practice Guideline for the Rehabilitation of Individuals With Lower Limb Amputation
1个月前
已完结
Lymph Node Pathologic Grading Strategy: under the backdrop of the IASLC Grading System for Invasive Lung Adenocarcinoma – a retrospective cohort study among Asian patients
1个月前
已完结
EGFR-targeted tyrosine kinase inhibitors: advancements in cancer therapy
2个月前
已完结
皖公网安备34019202002308
